## Biocon Limited (BIOCON) Stock Analysis - December 20, 2024

This report analyzes Biocon Limited's stock performance and financial health based on the provided data to determine whether it's a buy, sell, or hold.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                     |
|-----------------|--------------------------|
| Symbol           | BIOCON                    |
| Company Name     | Biocon Limited            |
| Industry         | Pharmaceuticals           |
| Listing Date     | April 7, 2004             |
| ISIN             | INE376G01013              |


**1.2 Market Data:**

| Metric                | Value     |
|-----------------------|------------|
| Last Price            | 336        |
| Change                | -14.35     |
| % Change              | -4.10%     |
| Previous Close        | 350.35    |
| Open                  | 350        |
| Close                 | 335.95    |
| VWAP                  | 340.48    |
| Week High             | 395.8      |
| Week Low              | 239.3      |
| Sector PE             | 22.95      |
| Symbol PE             | 22.23      |
| Total Traded Volume   | 2,889,197  |
| Delivery Quantity     | 1,301,339  |
| Delivery %            | 45.04%    |
| CM Daily Volatility   | 2.17       |
| CM Annual Volatility  | 41.46      |


**1.3 Corporate Actions:**

| Ex-Date      | Purpose                               |
|--------------|---------------------------------------|
| July 5, 2024  | Dividend - Re 0.50 Per Share          |
| July 7, 2023  | Dividend - Rs 1.50 Per Share          |
| June 30, 2022 | Dividend - Rs 0.50 Per Share          |
| July 18, 2019 | Dividend - Rs 0.50 Per Share          |
| June 12, 2019 | Bonus 1:1                             |
| July 19, 2018 | Dividend - Re 1 Per Share             |
| July 20, 2017 | Dividend - Re 1/- Per Share           |
| June 15, 2017 | Bonus 2:1                             |


**1.4 Recent Announcements:** (Last 5 shown)

| Broadcast Date     | Subject                                      |
|---------------------|----------------------------------------------|
| Dec 18, 2024        | Analysts/Institutional Investor Meet/Con. Call Updates |
| Dec 17, 2024        | Analysts/Institutional Investor Meet/Con. Call Updates |
| Dec 15, 2024        | Updates                                       |
| Dec 14, 2024        | Updates                                       |
| Dec 11, 2024        | Analysts/Institutional Investor Meet/Con. Call Updates |


**1.5 Financial Results (Last Five Quarters):**

| Quarter End     | Income     | Expenditure | Profit After Tax | EPS     |
|-----------------|------------|-------------|-----------------|---------|
| Sep 30, 2024    | 59,890     | 57,800       | 320              | 0.03    |
| Jun 30, 2024    | 55,250     | 55,140       | 90               | 0.01    |
| Mar 31, 2024    | 57,150     | 54,970       | 1,400            | 0.12    |
| Dec 31, 2023    | 61,130     | 57,840       | 2,400            | 0.20    |
| Sep 30, 2023    | 58,830     | 53,710       | 3,470            | 0.29    |


**1.6 Shareholding Patterns:**

Promoter holding has remained consistently at 60.64% over the last five quarters. Public shareholding has slightly increased.


**1.7 Board Meetings:** (Recent Meetings shown)

Board meetings were held on October 30, 2024, August 8, 2024, and May 16, 2024, primarily to review financial results and approve dividends.


**1.8 Key Management Personnel:**

(Partial list - only names and designations are provided in the data)

* Kiran Mazumdar Shaw: Chairperson, Executive Director
* Siddharth Mittal: Executive Director-CEO-MD
* Atul Dhawan: Independent Director
* Nicholas Robert Haggar: Independent Director
* Rekha Mehrotra Menon: Independent Director
* Naina Lal Kidwai: Independent Director
* Bobby Kanubhai Parikh: Independent Director
* Eric Mazumdar: Non-Executive Director
* Ravi Rasendra Mazumdar: Non-Executive Director


**2. Key Indicators:**

**2.1 Current Price Analysis:**

* The current price (336) is significantly lower than the previous close (350.35), indicating a negative trend.
* It's also below the week's high (395.8) and above the week's low (239.3).
* Pre-open activity showed a slight downward trend.


**2.2 Financial Performance:**

* Revenue shows some fluctuation but generally positive growth over the last five quarters.
* Profit after tax is highly variable, with significant swings between quarters.
* EPS also shows volatility, but generally positive.


**2.3 Shareholding Analysis:**

* Promoter holding remains stable at 60.64%, indicating strong insider confidence.


**2.4 Corporate Action Summary:**

* The company has a history of paying dividends, with a recent dividend of Re 0.50 per share.  Bonus issues have also occurred in the past.


**2.5 Volatility and Risk:**

* High CM Annual Volatility (41.46%) suggests the stock is relatively risky.


**3. Final Verdict:**

**Hold.**

While the recent price drop is concerning, and the financial performance shows volatility, the consistent promoter holding and history of dividend payouts suggest some underlying strength.  The high volatility, however, makes it a risky investment.  Further investigation into the reasons for the recent price drop and the variability in profitability is needed before considering a buy.  More data on the company's long-term prospects and competitive landscape would be beneficial for a more informed decision.

**Conclusion:**

Based solely on the provided data, Biocon Limited presents a mixed picture.  The stock's volatility and inconsistent profitability are significant concerns.  However, the stable promoter holding and history of dividend payments offer some reassurance.  A "hold" recommendation is given pending further analysis and clarification on the recent financial performance fluctuations.  A more comprehensive analysis incorporating external factors and future projections would be necessary to confidently recommend a "buy" or "sell" decision.
